Shares of Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) have been given a consensus rating of “Hold” by the seven ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $6.92.
Several brokerages have issued reports on CDLX. Evercore ISI started coverage on shares of Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target on the stock. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a report on Friday, January 17th. Finally, Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th.
Get Our Latest Research Report on CDLX
Cardlytics Stock Down 8.1 %
Cardlytics (NASDAQ:CDLX – Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. During the same quarter in the prior year, the firm posted ($0.26) EPS. The business’s revenue was down 15.1% on a year-over-year basis. On average, sell-side analysts anticipate that Cardlytics will post -1.52 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Amit Gupta sold 15,160 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $3.92, for a total transaction of $59,427.20. Following the transaction, the chief executive officer now directly owns 215,494 shares of the company’s stock, valued at approximately $844,736.48. The trade was a 6.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Alexis Desieno sold 25,118 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the sale, the chief financial officer now directly owns 116,481 shares of the company’s stock, valued at $399,529.83. This represents a 17.74 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,560 shares of company stock valued at $223,687. 4.40% of the stock is owned by company insiders.
Institutional Trading of Cardlytics
Hedge funds have recently modified their holdings of the stock. Tallon Kerry Patrick bought a new position in Cardlytics in the 4th quarter valued at about $37,000. Atom Investors LP acquired a new position in shares of Cardlytics in the third quarter valued at approximately $33,000. XTX Topco Ltd bought a new position in shares of Cardlytics during the second quarter worth approximately $107,000. SG Americas Securities LLC acquired a new stake in Cardlytics during the 3rd quarter worth approximately $45,000. Finally, Intech Investment Management LLC acquired a new stake in Cardlytics during the 3rd quarter worth approximately $47,000. Institutional investors and hedge funds own 68.10% of the company’s stock.
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
See Also
- Five stocks we like better than Cardlytics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What is a Death Cross in Stocks?
- 3 Steel Stocks Soaring After Tariff Announcements
- How to Invest in Insurance Companies: A Guide
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.